Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides

FOXO4-DRI

Other
Preclinical Research
15%
Moderate Risk
3/5

Dosing Protocol

Typical Dose 3 mg
Range 2 - 5 mg
Cycle 1w on / 4w off

Pharmacokinetics

Half-Life 4.0 hrs
Onset 1.0 hrs
Peak 6.0 hrs
Duration 1.0 days
Bioavailability 70%
Primary Route Subcutaneous

Administration

Routes Subcutaneous, Intravenous
Injection Sites Abdomen, Thigh
Needle Gauge 29-31G
Syringe Type Insulin
Timing intermittent, research protocol

Reconstitution

Diluent Bacteriostatic Water
Volume 1 mL
Stability 14 days refrigerated
Vial Sizes 5, 10 mg

Special Instructions

Experimental senolytic - intermittent dosing only (every 3+ weeks). D-retro-inverso modification provides protease resistance. 46 amino acids - expensive. Limited human data.